The year 2020 was a fruitful year for the South Korean companies and their R&D outcomes showcased in the global market.

Yuhan Corporation licensed out its novel lung cancer treatment ‘lazertinib’ to Janssen for 100 billion won. SK Biopharmaceutical put the gears in motion for its anti-epileptic drug Xcopri sales in the U.S. market.

The previously neglected diagnostic testing kit manufacturers emerged amid COVDI-19 as the success cases of the infectious disease prevention in South Korea. Samsung Bioepis and Celltrion broke the export record with their competitively priced biosimilars.

◆Yuhan’s Lazertinib confirms 100 percent response rate, the milestone pays out 100